ImmunoPrecise Antibodies Ltd.
US ˙ NasdaqCM ˙ CA45257F2008
ESTE SÍMBOLO NÃO ESTÁ MAIS ATIVO

SecurityIPA / ImmunoPrecise Antibodies Ltd.
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Latest Disclosed Ownership147,907 shares
Latest Disclosed Value $ 167,135
Citadel Advisors Llc ownership in IPA / ImmunoPrecise Antibodies Ltd.

On May 15, 2026 - Citadel Advisors Llc filed a 13F-HR form disclosing ownership of 147,907 shares of ImmunoPrecise Antibodies Ltd. (US:IPA) valued at $167,135 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 120,313 shares of ImmunoPrecise Antibodies Ltd.. This represents a change in shares of 22.94% during the quarter. The current value of the position is $306,167 USD.

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (IPA) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

IPA / ImmunoPrecise Antibodies Ltd. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F MINDWALK HOLDINGS COM 602687105 147,907 27,594 22.94 167 -23.39 0.0000
2026-02-17 2025-12-31 13F MINDWALK HOLDINGS COM 602687105 120,313 120,313 219 0.0000
2024-11-14 2024-09-30 13F IMMUNOPRECISE ANTIBODIES COM NEW 45257F200 0 -5,084 -100.00 0 -100.00
2024-08-14 2024-06-30 13F IMMUNOPRECISE ANTIBODIES COM NEW 45257F200 5,084 5,084 5 0.0000
2024-05-15 2024-03-31 13F IMMUNOPRECISE ANTIBODIES COM NEW 45257F200 0 -75,031 -100.00 0 -100.00
2024-02-14 2023-12-31 13F IMMUNOPRECISE ANTIBODIES COM NEW 45257F200 75,031 62,650 506.02 128 481.82 0.0000
2023-11-14 2023-09-30 13F IMMUNOPRECISE ANTIBODIES COM NEW 45257F200 12,381 -22,402 -64.41 23 -78.43 0.0000
2023-08-14 2023-06-30 13F IMMUNOPRECISE ANTIBODIES COM NEW 45257F200 34,783 -110,731 -76.10 103 -74.69 0.0000
2023-05-15 2023-03-31 13F IMMUNOPRECISE ANTIBODIES COM NEW 45257F200 145,514 104,794 257.35 403 87.44 0.0001
2023-02-14 2022-12-31 13F IMMUNOPRECISE ANTIBODIES COM NEW 45257F200 40,720 -21,641 -34.70 216 -13.65 0.0001
2022-11-14 2022-09-30 13F IMMUNOPRECISE ANTIBODIES COM NEW 45257F200 62,361 13,199 26.85 249 31.05 0.0001
2022-08-15 2022-06-30 13F IMMUNOPRECISE ANTIBODIES COM NEW 45257F200 49,162 49,162 190 0.0000
2022-05-16 2022-03-31 13F IMMUNOPRECISE ANTIBODIES COM NEW 45257F200 0 -52,966 -100.00 0 -100.00
2022-02-14 2021-12-31 13F IMMUNOPRECISE ANTIBODIES COM NEW 45257F200 52,966 -1,537 -2.82 284 -16.22 0.0001
2021-11-15 2021-09-30 13F IMMUNOPRECISE ANTIBODIES Cmn 45257F200 54,503 54,503 339 0.0001
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F MINDWALK HOLDINGS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-17 2025-12-31 13F MINDWALK HOLDINGS COM Call 116,700 9.07 212 13.37 n/a n/a n/a
2025-11-14 2025-09-30 13F MINDWALK HOLDINGS COM Call 107,000 187 n/a n/a n/a
2025-08-14 2025-06-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 59,500 118.75 63 530.00 n/a n/a n/a
2025-05-15 2025-03-31 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 27,200 10 n/a n/a n/a
2024-11-14 2024-09-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 14,100 -13.50 14 -41.67 n/a n/a n/a
2024-05-15 2024-03-31 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 16,300 -92.31 25 -93.37 n/a n/a n/a
2024-02-14 2023-12-31 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 211,900 1.24 362 -5.48 n/a n/a n/a
2023-11-14 2023-09-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 209,300 -3.90 383 -40.53 n/a n/a n/a
2023-08-14 2023-06-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 217,800 -1.54 645 5.23 n/a n/a n/a
2023-05-15 2023-03-31 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 221,200 -16.62 613 -56.47 n/a n/a n/a
2023-02-14 2022-12-31 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 265,300 0.76 1,406 33.78 n/a n/a n/a
2022-11-14 2022-09-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 263,300 -20.79 1,051 -18.08 n/a n/a n/a
2022-08-15 2022-06-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 332,400 12.07 1,283 -15.87 n/a n/a n/a
2022-05-16 2022-03-31 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 296,600 249.35 1,525 235.16 n/a n/a n/a
2022-02-14 2021-12-31 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 84,900 56.07 455 34.62 n/a n/a n/a
2021-11-15 2021-09-30 13F IMMUNOPRECISE ANTIBODIES Cmn Call 54,400 253.25 338 263.44 n/a n/a n/a
2021-08-16 2021-06-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Call 15,400 93 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F MINDWALK HOLDINGS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-17 2025-12-31 13F MINDWALK HOLDINGS COM Put 53,900 98 n/a n/a n/a
2024-11-14 2024-09-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Put 6,900 -33.01 7 -60.00 n/a n/a n/a
2024-05-15 2024-03-31 13F IMMUNOPRECISE ANTIBODIES COM NEW Put 10,300 -33.12 16 -42.31 n/a n/a n/a
2024-02-14 2023-12-31 13F IMMUNOPRECISE ANTIBODIES COM NEW Put 15,400 -24.14 26 -29.73 n/a n/a n/a
2023-11-14 2023-09-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Put 20,300 -15.77 37 -47.89 n/a n/a n/a
2023-08-14 2023-06-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Put 24,100 61.74 71 73.17 n/a n/a n/a
2023-05-15 2023-03-31 13F IMMUNOPRECISE ANTIBODIES COM NEW Put 14,900 -31.34 41 -64.35 n/a n/a n/a
2023-02-14 2022-12-31 13F IMMUNOPRECISE ANTIBODIES COM NEW Put 21,700 115 n/a n/a n/a
2022-11-14 2022-09-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-08-15 2022-06-30 13F IMMUNOPRECISE ANTIBODIES COM NEW Put 13,100 -40.18 51 -54.87 n/a n/a n/a
2022-05-16 2022-03-31 13F IMMUNOPRECISE ANTIBODIES COM NEW Put 21,900 -44.56 113 -46.70 n/a n/a n/a
2022-02-14 2021-12-31 13F IMMUNOPRECISE ANTIBODIES COM NEW Put 39,500 -39.04 212 -47.39 n/a n/a n/a
2021-11-15 2021-09-30 13F IMMUNOPRECISE ANTIBODIES Cmn Put 64,800 403 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.